Peptide briefings
News & research briefings
Editorial synthesis of recent peptide research, FDA regulatory actions, and trial readouts. Each briefing is written from primary sources (PubMed, ClinicalTrials.gov, FDA) and cross-links back into the PeptaHub peptide graph.
- Regulatory·1,050 words
PCAC Vote: Six Peptides Recommended for 503A Bulks List
FDA's advisers recommended BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for compounding eligibility. DSIP did not pass. What it does and doesn't change.
- Trial update·1,100 words
Orforglipron vs Oral Semaglutide: The ACHIEVE-3 Results
Lilly's oral GLP-1 pill beat oral semaglutide on every primary endpoint in the first head-to-head. What the ACHIEVE-3 numbers do and don't support.
- Regulatory·1,000 words
CagriSema FDA Decision Watch: What Q4 2026 Could Approve
CagriSema's FDA decision is expected this quarter. 22.7% weight loss, a divided head-to-head readout, and no approval anywhere yet.
- Regulatory·1,200 words
Orforglipron Clears EMA Panel: EU Approval Recommended
EMA's CHMP recommends Foundayo (orforglipron), Lilly's once-daily GLP-1 pill, for EU approval in weight management and type 2 diabetes. EC decision next.
- Regulatory·1,038 words
Navepegritide CHMP Opinion Puts TransCon CNP on EU Path
CHMP recommends EU approval of navepegritide (TransCon CNP), a once-weekly CNP prodrug for pediatric achondroplasia. EC decision expected Q4 2026.
- Regulatory·1,180 words
What the FDA's July 2026 Peptide Vote Actually Changes
FDA's advisers meet July 23-24 on seven peptides. Agency staff recommended against all seven. Even a favorable vote changes nothing on the day it happens.
- Regulatory·1,180 words
Peptide Reclassification Status — April 2026
Kennedy signaled ~14 peptides returning to 503A compounding; FDA removed 12 from Category 2. Neither made them compoundable. Updated after July's PCAC meeting.
- Safety·765 words
GLP-1s and Gastroparesis in 2026: Signal vs. Denominator
Adverse-event reports for GLP-1 gastroparesis have risen alongside prescribing. Raw counts don't establish risk — here's what the 2026 evidence base actually supports.
- Longevity·715 words
MOTS-c as an Exercise Mimetic: 2021–2025 Evidence
MOTS-c is a mitochondrial-derived peptide whose levels rise sharply with exercise. Recent work suggests it amplifies exercise adaptations — not that it replaces them.
- Trial update·770 words
GLP-1s and Primary Prevention: The SELECT Trial
SELECT showed a 20% MACE reduction in obese patients with prior CVD. Whether GLP-1s prevent first events without prior CVD is a separate, still-open question.
- Trial update·875 words
Retatrutide Evidence Into Mid-2026
The NEJM 2023 Phase 2 readout delivered up to 24.2% weight loss at 48 weeks. TRIUMPH-4 reported in December 2025; seven more Phase 3 readouts are expected through 2026.
- Safety·625 words
Melanotan II Safety in 2026: Case-Report Evidence
Peer-reviewed case reports have documented melanoma, renal infarction, and priapism linked to melanotan II since 2011 — the evidence has not aged well for cosmetic use.
- Regulatory·820 words
FDA Compounding Crackdown 2025: GLP-1 Access, Reshaped
The FDA declared the semaglutide and tirzepatide shortages resolved in 2025 and issued 50+ warning letters to compounders — here is what actually shifted.